Ömer KUTLU, Gökmen ZARARSIZ, Ragıp ERTAŞ, Kemal ÖZYURT, Muhammed Reşat AKKUŞ, Mustafa ATASOY, Ömer Faruk ELMAS, Ahu CEPHE, Fatma Nur KUTLU

Survival of biological therapeutics in psoriasis: retrospective analysis of 3-years data in a Turkish registry, PSORTAKSIS

Background/aim: PSORTAKSIS is a psoriasis registry, which is used for follow-up of patients in Kayseri City Education and Research Hospital, Dermatology Clinic since 2016 in Turkey. PSORTAKSIS includes demographic data, follow-up clinical findings, laboratory output, and treatment information of patients. Here, drug survivals of biologic therapeutics (BT) according to three-year data of PSORTAKSIS will be presented. Materials and methods: Drug survival of BT in PSORTAKSIS was analyzed from 2016 to March 2019. Results: 158 patients (111 of them BT-naive) with psoriasis under BT were enrolled in the current study. Drug survival analysis of patients with ongoing BT (158 treatment periods) revealed mean survival time as 15.49 months for ustekinumab, 15.37 months for adalimumab, 14.00 months for etanercept, 5 months for infliximab, and 4.59 months for secukinumab. The differences between drug survivals of BT were statistically significant (log-rank test, χ2 = 79.915, p < 0.0001). Age of onset was found to be the only independent risk factor of drug survival according to regression analysis (p = 0.029). Conclusion: As a conclusion, drug survival of UST was significantly higher than that of TNF-alpha inhibitors and SEC in the treatment of psoriasis. This study revealed that among predictors, age at disease onset may influence drug survival.

PDF

___

1. Carneiro C, Bloom R, Ibler E, Majewski S, Sable KA et al. Rate of serious infection in patients who are prescribed systemic biologic or nonbiologic agents for psoriasis: A large, single center, retrospective, observational cohort study. Dermatologic Therapy 2017; 30 (5): e12529. doi: 10.1111/dth.12529
2. Özyurt K, Ertaş R, Atasoy M. Biologics for psoriasis: What is new? Dermatologic Therapy 2019; 32 (3): e12916. doi: 10.1111/ dth.12916
3. Özyurt K, Avcı A, Ertaş R, Ulaş Y, Akkuş MR et al. PSORTAKSİS: Kayseri Sağlık Uygulama ve Araştırma Merkezi Dermatoloji Kliniği’nde kullanılan yeni bir psoriasis hasta kayıt sistemi. Turk Dermatoloji Dergisi 2018; 12 (1): 23-27. doi: 10.4274/tdd.3418
4. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F et al. A checklist for medication compliance and persistence studies using retrospective databases. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2007; 10 (1): 3-12. doi: 10.1111/j.1524- 4733.2006.00139.x
5. Galache Osuna C, Gómez-Vila B, Aubán Pariente J, Vázquez Losada B, Gómez de Castro C et al. Ustekinumab drug survival in patients with psoriasis: A retrospective study of real clinical practice. Medicina 2020; 56 (11): 584. doi: 10.3390/ medicina56110584
6. No DJ, Inkeles MS, Amin M, Wu JJ. Drug survival of biologic treatments in psoriasis: a systematic review. Journal of Dermatological Treatment 2018; 29 (5): 460-466. doi: 10.1080/09546634.2017.1398393
7. Benner JS, Tierce JC, Ballantyne CM, Prasad C, Bullano MF et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004; 22 (Suppl 3): 13-23. doi: 10.2165/00019053-200422003- 00003
8. Costanzo A, Malara G, Pelucchi C, Fatiga F, Barbera G et al. Effectiveness end points in real-world studies on biological therapies in psoriasis: Systematic review with focus on drug survival. Dermatology 2018; 234 (1-2): 1-12. doi: 10.1159/000488586
9. Mourad A, Straube S, Armijo-Olivo S, Gniadecki R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. British Journal of Dermatology 2019; 181 (3): 450-458. doi: 10.1111/bjd.17738
10. Özyurt K, Ertaş R, Avcı A, Akkuş MR, Atasoy M. Chronic skin disease unit and internal counseling in an outpatient dermatology clinic: Collaboration of dermatologists in dermatology practice. İstanbul Kanuni Sultan Süleyman Tıp Dergisi 2020; 12 (2): 156-158. doi: 10.5222/iksstd.2020.81994
11. Dogra S, Mahajan R. Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatology Online Journal 2016; 7 (6): 471-480. doi: 10.4103/2229- 5178.193906
12. Hajiebrahimi M, Song C, Hägg D, Andersson TM, Villacorta R et al. The occurrence of metabolic risk factors stratified by psoriasis severity: A Swedish population-based matched cohort study. Clinical Epidemiology 2020; 12: 737–744. doi: 10.2147/CLEP.S252410
13. Puig-Sanz L. Psoriasis, a systemic disease? Actas DermoSifiliográfica 2007; 98 (6): 396-402. doi: 10.1016/S0001- 7310(07)70092-3
14. Gladman DD. Psoriatic arthritis. Dermatologic Therapy 2004; 17 (5): 350-363. doi: 10.1111/j.1396-0296.2004.04038.x
15. Stuart P, Malick F, Nair RP, Henseler T, Lim HW et al. Analysis of phenotypic variation in psoriasis as a function of age at onset and family history. Archives of Dermatological Research 2002; 294 (5): 207-213. doi: 10.1007/s00403-002-0321-3
16. Turkish Guideline for the Treatment of Psoriasis-2016. Turkderm-Arch Turk Dermatol Venerology 2016; 50 (Suppl.1): 1-56.
17. Iannone F, Santo L, Bucci R, Semeraro A, Carlino G et al. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE). Clinical Rheumatology 2018; 37: 667– 675. doi: 10.1007/s10067-018-3989-2
18. Warren RB, Smith CH, Yiu ZZ, Ashcroft DM, Barker JNW et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). The Journal of Investigative Dermatology 2015; 135 (11): 2632-2640. doi: 10.1038/jid.2015.208
19. Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S et al. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. British Journal of Dermatology 2015; 172 (1): 244-252. doi: 10.1111/bjd.13343
20. Puig L, Ruiz-Salas V. Long-term efficacy, safety and drug survival of ustekinumab in a Spanish cohort of patients with moderate to severe plaque psoriasis. International Journal for Clinical and Investigative Dermatology 2015; 230: 46-54. doi: 10.1159/000366499
21. Van den Reek JM, Tummers M, Zweegers J, Seyger MM, van Lümig PP et al. Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry. Journal of the European Academy of Dermatology and Venereology 2015; 29 (3): 560- 565. doi: 10.1111/jdv.12636
22. Menter A, Papp KA, Gooderham M, Pariser DM, Augustin M et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal of European Academy of Dermatology and Venereology 2016; 30 (7): 1148-1158. doi: 10.1111/jdv.13611
23. Iskandar IYK, Warren RB, Lunt M, Mason KJ, Evans I et al. Differential drug survival of second-line biologic therapies in patients with psoriasis: Observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). The Journal of Investigative Dermatology 2018; 138 (4): 775-784. doi: 10.1016/j.jid.2017.09.044
24. Zeb L, Mhaskar R, Lewis S, Patel NS, Sadhwani D et al. Realworld drug survival and reasons for treatment discontinuation of biologics and apremilast in patients with psoriasis in an academic center. Dermatologic Therapy 2021; 34 (2): e14826. doi: 10.1111/dth.14826
25. Egeberg A, Ottosen MB, Gniadecki R, Broesby-Olsen S, Dam TN et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. British Journal of Dermatology 2018; 178 (2): 509-519. doi: 10.1111/ bjd.16102
26. Richter L, Vujic I, Sesti A, Monshi B, Sanlorenzo M et al. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria. Journal der Deutschen Dermatologischen Gesellschaft 2017; 15 (3): 309- 317. doi: 10.1111/ddg.13191
27. Garcia-Doval I, Dávila-Seijo P. How real are ‘real-life studies’ in psoriasis, and the uncertain meaning of drug persistence. British Journal of Dermatology 2019; 180 (1): 15-16. doi: 10.1111/bjd.17104
28. Jacobi A, Rustenbach SJ, Augustin M. Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis. International Journal of Dermatology 2016; 55 (3): 296-302. doi: 10.1111/ijd.12879
29. Shalom G, Cohen AD, Ziv M, Eran CB, Feldhamer I et al. Biologic drug survival in Israeli psoriasis patients. Journal of the American Academy of Dermatology 2017; 76 (4): 662-669. e1. doi: 10.1016/j.jaad.2016.10.033